SMS PharmaceuticalsQ4 FY23

SMS Pharmaceuticals Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹486.5P/E: 39.0Market Cap: ₹4.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

No

Order

Yes

Capex

No

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company expects around 20% topline (revenue) growth in FY2024 compared to FY2023.
  • Growth drivers include existing businesses, ARV segment revival, anti-diabetic segment, and Ibuprofen volumes.
  • ARV business contribution is anticipated to be around 20% in coming quarters, marking a recovery from previous low levels.
  • Capacity utilization is targeted to improve to 75-80% in FY2024, supporting volume growth.
  • Ibuprofen commercial capacity is expanding from 300 MT to 700-900 MT per month within six months, aiding volume increase.
  • The company aims to consolidate current capacities before future expansions, with no major capex planned in FY2024.
  • Growth is expected to be supported by increased domestic and semi-regulated market presence, particularly for products like alfuzosin.

See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • No major capex or new fundraising planned for FY2024 as the company aims to consolidate cash flows and revenue.
  • No current plans for Greenfield or Brownfield expansions, indicating limited immediate need for debt or equity raising.
  • Regular maintenance capex only, suggesting stable capital expenditure without large funding requirements.
  • Any major capex or fundraising may be considered from FY2025 onwards, depending on FY2024 performance.
  • Overall focus is on optimizing existing operations and R&D for margin improvement rather than expansion requiring external funding.

See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

No
  • No major capex planned for FY2024; focus is on consolidating cash flows and driving revenue growth first.
  • Only regular, normal plant maintenance capex expected in FY2024, nothing extraordinary.
  • No plans for Greenfield or Brownfield expansions currently; company prefers to consolidate operations before new projects.
  • Potential capex may be considered in FY2025 depending on FY2024 performance.
  • R&D investment is focused on cost optimization, backward integration (making intermediates and KSMs in-house), and exploring new therapeutic categories.
  • Increasing capacity utilization (targeting 75-80% for FY2024) before pursuing any capacity expansions.

Track SMS Pharmaceuticals — get its next earnings analysis in your feed

How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSMS Pharmaceuticals
Rev 2Mar 1

How does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →